Purpose. In this field trial of rapid blood culture identification (BCID), we aimed to determine whether the improved speed and accuracy of specific BCID predicted in our earlier pilot study could be obtained in regional hospitals by deploying a multiplex PCR FilmArray (Biomerieux, France) capability in their laboratories.
INTRODUCTION
Prompt introduction of effective antimicrobial therapy is the key to successful treatment of sepsis [1] . The standard means of determining the cause of sepsis is detection of bacteraemia by blood culture, identification of these bacteria and determination of their antimicrobial susceptibility. Although sepsis is considered to be a time-critical medical emergency [1] [2] [3] , a recent study claimed that a delayed start to antimicrobial therapy in the early stages of hospital admission did not adversely affect outcomes [4] . However, if started early in the hospital admission, an admitting physician is forced to make a presumptive choice of antibiotic because blood culture results are usually not available in the first 12-24 h after admission. The United Kingdom's O'Neill Commission on Antimicrobial Resistance emphasized the need for much faster diagnostic tests if their results are going to be used to justify antibiotic use [5] . An increasing variety of rapid bacterial identification techniques are available and are becoming the new standard of laboratory practice for large hospitals [6] . The interval between blood culture collection and definitive bacterial identification can be as low as 5-8 h in a teaching hospital with a MALDI-TOF-equipped microbiology laboratory. However, smaller hospitals with limited clinical microbiology services are unable to meet these turnaround times. In Western Australia (WA), clinical pathology laboratories can be thousands of kilometres away from these advanced bacterial identification and susceptibility test services. These hospitals have limited on-site clinical microbiology services, no onsite MALDI-TOF and long distances for specimen referral, and have to cope with the constraints of an infrequent air transport network. These smaller hospitals therefore have to transfer blood cultures, patients, or both to larger regional centres. In a previous assessment of multiplex PCR BCID we assessed the feasibility of substituting MALDI-TOF BCID with FilmArray in regional hospital laboratories, established good coverage of the range of bacterial species encountered in regional centres and estimated a 52 h reduction in time to definitive isolate identity [7] . Subsequent trials by other groups confirmed a substantial reduction in the time to a confirmed BCID result, and established the superiority of FilmArray over MALDI-TOF for BCID and the superior performance of FilmArray with mixed blood cultures [8, 9] . Our previous study took place before regulatory approval for clinical use of the BCID FilmArray results and therefore did not investigate FilmArray's impact on clinical laboratory practice in regional centres [7] . Subsequent approval for clinical use of the BCID FilmArray in Australia allowed us to introduce BCID FilmArray and assess its impact on regional hospital laboratory practice. In this study we assessed the technical feasibility of embedding BCID FilmArray in regional hospital laboratory workflows, its impact on laboratory reporting of preliminary blood culture results in regional hospitals and its potential effect on specimen and patient referral.
METHODS
A single FilmArray platform (BioFire, BioMerieux, Marcy L'Etoile, France), computer and proprietary software were obtained on loan from the manufacturer, under supervision of the Research Development Unit, Department of Health, Government of Western Australia, for use in a Health Department-funded research translation project on rapid diagnosis of severe infection in regional Western Australia. The BCID FilmArray is able to identify 27 specific bacterial targets, including the commonest species isolated from blood cultures [7] . Within-date blood culture identification (BCID) FilmArray pouches were distributed via the central laboratory at the Queen Elizabeth II Medical Centre, where equipment checks were conducted prior to installation, training and operation in the two regional centres.
The two centres chosen were the regional centres with the highest annual turnover of blood cultures that operated throughout the working week, with out-of-hours emergency cover. These were (a) Bunbury, just over 200 km to the south of Perth and accessible by road, and (b) Broome, around 2000 km to the north of Perth and normally accessed by air. Their standard BCID workflow is triggered by a blood culture autoanalyser positive signal, and proceeds to Gram stain followed by subculture and subsequent culture-dependent bacterial identification and susceptibility tests. All significant bacterial isolates from these regional laboratories are referred to the central laboratory for confirmation of identity and antimicrobial susceptibility tests.
The BioFire platform, peripherals and a box of 30 BCID FilmArray pouches were deployed first to the PathWest laboratory at Bunbury Health Campus by road, and the laboratory staff there were trained in its operation with machine-positive blood cultures. Resupply of BCID FilmArray pouches was required once during the trial period. The BioFire platform, peripherals and remaining unused pouches were retrieved, and the process was repeated with the PathWest laboratory at Broome Health Campus, using scheduled commercial air services to deploy the equipment, trainer and pouches. While no restrictions were placed on the times of Biofire operation, this was generally during laboratory opening hours on weekdays.
The BCID FilmArray results were saved in Portable Document Format (PDF) files and scanned into the laboratory information system (LIS), and the result communications were recorded according to standard laboratory practice. Positive FilmArray results were notified to hospital staff using a similar process to that for preliminary Gram-stain results, while a clinical microbiologist in Perth was also notified. When multiple or repeat positive bottles were obtained from the same patient, the clinical microbiologist was contacted for guidance on whether or not to use BCID FilmArray and on which culture bottles. On completion of the trial period at each site, the list of blood culture episodes investigated by FilmArray was retrieved, and the definitive blood culture results, specimen journey time points, clinical advice and patient movements were recorded.
The recorded time points in the blood culture workflow were identified from the electronic LIS (ULTRA v 1.4, PathWest Laboratory Medicine, WA Health). Time was calculated between key points in the specimen journey, starting with the recorded time of specimen collection. Baseline historical control data on conventional culture-based BCID time intervals were obtained for the identical period at each regional centre during the previous year. Data on the date and time of patient movements between public hospitals were obtained through the electronic records of the statewide LIS and supplemented by the clinical microbiologist's written advice in the electronic record.
Significant and non-significant but discrepant blood culture isolates were sent to the main Perth laboratory for MALDI-TOF, rapid PCR assay (GeneXpert, Cepheid, CA, USA), extended susceptibility tests and storage according to the PathWest branch laboratory's standard procedure. Additional analysis was conducted on discrepant blood culture isolates to obtain definitive BCID. This entailed repetition of BCID FilmArray after repeated subculture of blood culture bottles, plus 16 s sequence analysis of isolates that were unidentified by other means, such as MALDI-TOF mass spectroscopy, VITEK2, substrate utilization panel or specific rapid tests.
The data were assembled in Excel v 7.3 and analysed using Prism 6.0 (GraphPad, San Diego, CA, USA).
The project was conducted as a clinical laboratory quality initiative, under the research governance of the Research Development Unit, Department of Health, Government of Western Australia.
RESULTS
One hundred and eleven BCID FilmArray panels were run in two regional laboratories between September 2015 and March 2016. One hundred auto-analyser (BacTec 9240 or 9050, Becton Dickinson) positive blood culture episodes were assessed after the exclusion of FilmArray panels used for specimens other than blood culture, duplicate blood culture bottles within the same set, repeat FilmArray results from the same clinical episode, or FilmArray panels used to check unexpected blood culture results ( Fig. 1 ). These 100 episodes comprised 37 from the Bunbury laboratory and 63 from the Broome laboratory. The corresponding blood cultures were collected from hospitals in Broome (35) and Bunbury (29), smaller referring hospitals in Fitzroy Crossing (13), Halls Creek (8), Busselton (3) and Harvey (3) , and clinics at Bidyadanga (3), Broome (2), Beagle Bay (1), Donnybrook (1), Mandurah (1) and Noonkanbah (1).
The BCID FilmArray result matched the definitive conventional identification (as defined in laboratory standard operating procedures, normally requiring either MALDI-TOF identification at or above an index of 2.00) within the scope of the bacterial species and its antimicrobial resistance mechanisms in the 27-plex FilmArray panel in all 42 significant monobacterial cultures, with a fully predictive identity in 38 (90.5 %) and a partial identity in another 4 (9.5 %). The FilmArray was therefore partially or wholly predictive in 98 % of significant monobacterial episodes (Table 1) . Of the seven significant polymicrobial clinical specimens, five isolates were correctly identified for all species to genus level and in three all species were fully identified. Eight bacterial cultures contained species outside the scope of the FilmArray, including Neisseria cinerea, Acinetobacter species other than A.baumannii, Chryseomonas species, Stenotrophomonas maltophilia, Pseudochrobactrum asaccharolytica, Anaerococcus species, Rhodococcus species and an unidentified Gram-negative bacillus. There was one major error of potential clinical consequence: a false positive Pseudomonas aeruginosa result. The other discrepant results were less significant. A mixed methicillin-susceptible Staphylococcus aureus (MSSA) and methicillin-resistant Staphylococcus epidermidis produced a result that was interpreted as a methicillin-resistant S. aureus (MRSA), and there were four false negative coagulase-negative staphylococci by culture ( Table 1) . The other bacterial species outside the scope of the BCID FilmArray were all in mixed cultures and were considered to represent contamination. The 24 negative FilmArray results included eight autoanalyser-positive/Gramstain and culture-negative blood culture episodes. In all, there were 11 negative FilmArray resukts from blood cultures containing isolates judged to be non-significant, including four coagulase-negative staphylococci, five Micrococcus, one Corynebacterium and one Propionibacterium species.
Despite the operation of the FilmArray BCID being predominantly during daytime laboratory hours, the time to FilmArray BCID was more than 1 day faster than the earliest stages of secondary culture-based BCID, definitive identification by MALDI-TOF or an alternative ( Table 2 ). The communication of the BCID FilmArray results was not significantly later than Gram-stain reporting, though the FilmArray results were a more complete bacterial identification. The time taken to generate a FilmArray result and communicate it to the treating doctor differed between the four regional centres in northern WA that collected the most blood cultures (Table 3 ). There was a significant difference between the time to BCID for Broome District Hospital and the Fitzroy Crossing Hospital that referred on to Broome (Mann-Whitney U test, U=128, P=0.0265). When comparing the BCID FilmArray trial series with a historical period (the previous year) (Table 4) , there was no significant difference in the median time to early blood culture results (Gram stain) or the initial communication of these results to treating physicians. These two periods differed in that the results communicated during the comparison period with the treating physician were only those for Gram stains, and in the trial period a more complete identification was provided by the FilmArray results. The difference between identification by FilmArray during field trials and identification by referral to the central laboratory in Perth during the During the field trial period, 27 patients were transferred by ambulance between centres with or because of suspected sepsis (Table 5 ). Of these, 12 (44 % transfers) were transferred long distance by air ambulance between northwestern hospitals and a Perth teaching hospital, or from outlying clinics into Broome District Hospital. Nineteen out of fiftyseven (33 %) patients with significant blood culture results and 8/43 (18.6 %) with non-significant results were transferred (total transfer, 27 %). Two patients from southwestern regional hospitals were transferred by road from Bunbury to Perth for higher acuity care, and three patients were transferred between an outlying centre and Bunbury. No patients were transferred by air from these centres during the period under study. No comparison with the previous year was possible due to differences in providing inter-hospital transfer.
DISCUSSION
WA covers an area similar in size to Western Europe (Fig. 2) , and is the largest sub-national government jurisdiction in the world. Outlying public hospitals are more selfsufficient in major clinical specialties than the similarly sized district hospitals closer to the Perth metropolitan area featured in our previous BCID FilmArray study [7] . On a European scale, the flights taken to transfer patients or their blood cultures are similar to the distance between Stavanger in Norway and Aberdeen in the United Kingdom. Transfer to a teaching hospital involves a longer distance flight than would be required to fly between Aberdeen and Barcelona in Spain. In WA, clinical support services such as advanced microbiology are highly centralized, with limited culturebased services and no molecular microbiology outside the metropolitan area. Laboratory support for sepsis management is challenging over these distances. The self-contained BCID FilmArray offers a potential means of delivering faster identification of bacteraemic infection at remote locations. Our previous assessment addressed the microbiology service to non-teaching hospitals that referred their blood cultures to the main teaching hospital laboratory, and conducted the study before regulatory approval for clinical use of the BCID FilmArray results [7] . From that study we expected a 1-2 day reduction in turnaround time, without any loss of diagnostic accuracy. We had also noted a greater accuracy in BCID by FilmArray than by MALDI-TOF (Sepsititre, Bruker, Germany) for those species isolated from regional hospital patients. A superior performance to MALDI-TOF BCID has been noted in other recent studies, due to suboptimal MALDI-TOF performance with bacterial species such as Streptococcus pneumoniae and mixed cultures [8] [9] [10] . In the present study, MALDI-TOF BCID was restricted to use as one component of definitive bacterial identification for isolates referred from the participating regional laboratories. None of our regional clinical laboratory centres is equipped with a MALDI-TOF mass spectrophotometer, because the bacteriology workload in the larger (100) 16 (100) a, Patient transfer from location where blood culture collected to other public hospital or from clinic to hospital as recorded in laboratory information system. b, Transfer to or between hospitals requiring an aeromedical flight.
c, Blood culture results at or immediately before patient transfer considered reason for definitive antimicrobial therapy.
regional laboratories is insufficient to justify the cost of the installation, operation and maintenance of a MALDI-TOF service. A less cumbersome solution, such as the BCID FilmArray, is therefore needed. The common bacterial isolates from participating regional laboratories fall within the scope of specific bacterial targets selected for the BCID panel [7] . Indeed, in the present study the majority of isolates that were not detected by FilmArray were deemed to have been contaminating skin bacteria. The one Acinetobacter isolate was a species other than A. baumannii and therefore outside the scope of the BCID FilmArray. The false positive Pseudomonas aeruginosa result has no clear explanation, despite extensive further investigation, including repeat FilmArray analysis, which was negative, suggesting borderline or low concentration molecular contamination. Other reports of occasional false positive FilmArray results for P. aeruginosa raise the possibility of within-bottle action of an anti-pseudomonal antibiotic, or contamination with traces of bacterial DNA during blood culture bottle manufacture [11] . The false positive MRSA result was interpreted as being the result of a combination of a MSSA and methicillin-resistant coagulase-negative staphylococcus, seen with other molecular bacteriological methods [12] , and confirmed on this occasion by conventional culture-based methods. These and the four coagulase-negative staphylococci results that the FilmArray missed reinforce the value of using the Gram stain on autoanalyzer-positive blood cultures to assist with the interpretation of FilmArray results. In the present field trial, FilmArray added considerable value to the preliminary Gram stain result around 1 hour later, and therefore brought definitive BCID, including differentiation between MSSA and MRSA, closer to preliminary microscopy. The rapid confirmation of a FilmArray-negative result for an autoanalyser positive blood culture that has no bacteria on the Gram stain was a potential opportunity to avoid unnecessary antimicrobial therapy. FilmArray produced a median reduction in time to definitive BCID of 2.7 days, compared to the service offered by centralized BCID 1 year previously. This comprises the reduction achieved by local performance of preliminary BCID (1.2 days) compared to culture-dependent identifications completed in the referral laboratories during the control period.
There is a need for further investigation of the possible second-order effects of introducing molecular methods to regional centres, such as an impact on patient and specimen onward referral. The lengthy distances between the outlying regional hospitals and the larger regional centres resulted in the addition of another day to specimen processing times due to their transport between hospitals. The LIS records instances where physicians were able to commence targeted antimicrobial therapy for patients with sepsis sooner than they would if relying on culture-based BCID. In outlying hospitals there were recorded cases of sepsis management without a need for aeromedical evacuation (AME) to a larger hospital. Nevertheless, one-third of patients with clinically significant bacteraemia in this study still required inter-hospital transfer. The majority of patients with sepsis during the second part of this field trial were indigenous. Inter-hospital transfer would require leaving their traditional country for hospital treatment and may therefore deter early presentation for in-patient admission. The potential impact of near-patient BCID services for our indigenous population needs further investigation. Early identification of this single commonest blood culture isolate, coagulase-negative staphylococci, enabled the laboratory to provide much earlier guidance to the treating physician, enabling early de-escalation of intravenous antibiotic therapy, with potentially faster hospital discharge and overall improvement in antibiotic stewardship.
The present field trial covered two regional centres and their respective smaller hospital dependencies. The southerly location is accessible from Perth by road, but too far for helicopter (rotary-wing AME) and not far enough for fixedwing AME. Courier services are too infrequent to accommodate urgent specimen transfer, hence a locally performed molecular test method remains an attractive solution to the delays built into the current specimen transport network. The FilmArray produced a Neisseria meningitidis-positive result from a blood culture 9 hours after specimen inoculation during a weekend; a result that was not confirmed by referral for culture-dependent methods until over 72 h after specimen collection. The smaller regional hospitals in the tropical north of the state were able to obtain results that enabled directed antimicrobial therapy for S. aureus and S. pyogenes without transferring patients. The question has to be asked whether the greatest benefits of BCID FilmArray capability might be seen in some of the smaller hospitals furthest from the reference laboratory centres. Successful operation of the BCID FilmArray has already been demonstrated with 'non-expert' staff in other trials [13] . Having demonstrated the feasibility of decentralized rapid blood culture identification in regional Western Australia, we now recognize the need to analyse its economic consequences and model the best fit to service delivery [14] .
We have demonstrated the feasibility, accuracy and sustainability of molecular diagnostic methods in two remote regional hospitals in a field trial of the BCID syndromic PCR array panel. Our findings identify a practical means of achieving specific improvements and enhancements to current regional clinical microbiology services, without the local installation of MALDI-TOF mass spectrometry. The time-critical nature of sepsis, the frequency with which sepsis contributes to patient transfer by AME for higher acuity care and the predominance of indigenous patients highlight the potential for near-patient molecular diagnostics to raise the quality of care for patients with sepsis in regional Australia.
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